BICO Group AB engages in the provision of technologies, products, and services to create, understand, and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 586 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
최신 재무제표(Form-10K)에 따르면, BICO Group AB (publ)의 총 자산은 $3,696이며, 순손실입니다.
BCCOY의 주요 재무 비율은 무엇인가요?
BICO Group AB (publ)의 유동비율은 1.89이고, 순이익률은 -72.67, 주당 매출은 $21.21입니다.
BICO Group AB (publ)의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
BICO Group AB (publ) 주요 수익원은 Life Science Solutions이며, 최신 수익 발표에서 수익은 1,009,100,000입니다. 지역별로는 United States이 BICO Group AB (publ)의 주요 시장이며, 수익은 1,162,800,000입니다.
BICO Group AB (publ)은 수익성이 있나요?
no, 최신 재무제표에 따르면 BICO Group AB (publ)의 순손실은 $-1,088입니다.